Quantcast

Latest Dry powder inhaler Stories

2014-06-24 23:06:47

According to a new report from BCC Research, the global market for pulmonary drug delivery systems is expected to grow to $43.9 billion by 2018 with a compound annual growth rate (CAGR) of 6.2% from 2013 to 2018. The dry powder inhalers category is the fastest moving segment in this market, growing at a significant five-year CAGR of 12.5%. (PRWEB) June 24, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, PULMONARY DRUG DELIVERY SYSTEMS: TECHNOLOGIES AND GLOBAL...

2014-05-15 04:22:31

OXFORD, England, May 15, 2014 /PRNewswire/ -- First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix' novel particle-engineering technology Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it will present results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive...

2014-05-02 23:05:28

Live webinar to focus on the interaction between inhalation powders and capsules shells, giving guidance to formulators on how best to tackle potential challenges. The broadcast takes place on Thursday, May 22, 2014 at 9:00 EDT (14:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) May 02, 2014 This webinar will explore the relationship between dry powder inhalers and hard capsules, how to match them together to give good powder aerosolization and delivery of the active ingredient deep into the...

2014-04-07 12:23:29

LISBON, Portugal, April 7, 2014 /PRNewswire/ -- Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application. Hovione have designed this inhaler to have just two operating components, thereby achieving...

2014-03-31 23:35:56

Next Breath is now authorized to conduct Pharmaceutical Equivalence studies for Brazil. Baltimore, Maryland (PRWEB) March 31, 2014 Next Breath, LLC is pleased to announce that the Brazilian National Sanitary Surveillance Agency (ANVISA) has certified the company as a Center for Pharmaceutical Equivalence (EQFAR). As a result, Next Breath is now authorized to conduct Pharmaceutical Equivalence studies for Brazil. ANVISA performed a week-long comprehensive audit of Next Breath’s quality...

2014-02-25 08:32:43

ALBANY, New York, February 25, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Pulmonary Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global pulmonary drug delivery systems market was valued at USD 21.03billion in 2012 and is expected to grow...

2014-02-14 12:24:25

DUBLIN, February 14, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/477x2k/drug) have announced the addition of the "Drug Self-administration Markets to 2020" [http://www.researchandmarkets.com/research/477x2k/drug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Therapeutic Indications, Product Strategies, Markets and Forecasts While alternative methods for delivering...

2014-01-23 04:21:29

OXFORD, England, January 23, 2014 /PRNewswire/ -- First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA) Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with...

2014-01-02 23:22:46

Transparency Market Research Report added "Drug Device Combination Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" to its database. Browse full report with TOC: http://www.transparencymarketresearch.com/drug-device-combination.html. Albany, New York, USA (PRWEB) January 02, 2014 According to a new market report published by Transparency Market Research "Drug Device Combination Products Market (Drug Eluting Stents, Infusion...

2013-11-19 23:32:03

Achieve is conducting a safety and efficacy study on a new combination asthma treatment versus an inhaled treatment for adolescents and adult patients with asthma. Birmingham, Alabama (PRWEB) November 19, 2013 *To see if you qualify for this Asthma Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive compensation for...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related